Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Short-term Investments (2021 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Short-term Investments for 5 consecutive years, with $241000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Short-term Investments fell 50.82% to $241000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $241000.0, a 50.82% decrease, with the full-year FY2024 number at $22000.0, down 89.42% from a year prior.
  • Short-term Investments was $241000.0 for Q3 2025 at Xtant Medical Holdings, up from $114000.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $490000.0 in Q3 2024 to a low of $22000.0 in Q4 2024.
  • A 5-year average of $222500.0 and a median of $212000.0 in 2021 define the central range for Short-term Investments.
  • Biggest YoY gain for Short-term Investments was 476.47% in 2024; the steepest drop was 89.42% in 2024.
  • Xtant Medical Holdings' Short-term Investments stood at $144000.0 in 2021, then soared by 45.14% to $209000.0 in 2022, then dropped by 0.48% to $208000.0 in 2023, then tumbled by 89.42% to $22000.0 in 2024, then skyrocketed by 995.45% to $241000.0 in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Short-term Investments are $241000.0 (Q3 2025), $114000.0 (Q2 2025), and $403000.0 (Q1 2025).